SLU-PP-332
Evidence: DMetabolic / Weight Management
Evidence Snapshot
What this grade covers
A for chemical identity and pan-ERR agonism; B for selected cell and mouse findings; E for human exercise, obesity, diabetes, heart-failure, kidney, anti-aging, performance, safety, approval, or dosing claims.
Regulatory Context
Preclinical research compound; no direct human administration trial or FDA-approved marketed medicine was verified in this review.
Research Takeaway
SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors ERRα/β/γ; despite its frequent appearance in peptide catalogs, it is not a peptide and must be distinguished from SLU-PP-915 and later orally optimized analogs.
Evidence boundary: Scaffold descendants are distinct compounds with potentially different pharmacokinetics and potency.
See all 6 evidence claims →Quick Summary
SLU-PP-332 is an experimental small-molecule ERR agonist with mouse and cell evidence related to oxidative metabolism, endurance, metabolic syndrome, kidney aging, and heart failure models. In vitro metabolism and analytical-chemistry studies (including doping-control-oriented work) have characterized SLU-PP-332 and the related, distinct compound SLU-PP-915 using human liver fractions -- laboratory material, not human administration.
Mechanism & Research Overview
SLU-PP-332 is a synthetic small-molecule pan-estrogen-related-receptor agonist studied for effects on mitochondrial oxidative metabolism. It is not a peptide and should not be described as one.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors ERRα/β/γ; despite its frequent appearance in peptide catalogs, it is not a peptide and must be distinguished from SLU-PP-915 and later orally optimized analogs.
Does not establish
Evidence boundary: Scaffold descendants are distinct compounds with potentially different pharmacokinetics and potency.
Sources: Orally Active ERR Agonist Developed From SLU-PP-332 Scaffold
Supported
In mice, SLU-PP-332 activated ERR-linked transcriptional programs associated with oxidative skeletal-muscle phenotype and exercise-like metabolic adaptation.
Does not establish
Evidence boundary: Molecular mimicry of selected exercise adaptations is not equivalent to the full physiologic effects of exercise.
Supported
SLU-PP-332 increased exercise endurance/capacity in mouse experiments.
Does not establish
Evidence boundary: Mouse endurance findings do not establish athletic-performance, weight-loss, or cardiometabolic efficacy in humans.
Supported
In mouse metabolic-disease models, SLU-PP-332 increased energy expenditure and improved selected features of metabolic syndrome.
Does not establish
Evidence boundary: These preclinical findings cannot be converted into expected human fat-loss percentages or therapeutic outcomes.
Supported
Later medicinal-chemistry programs explicitly developed new orally active or optimized compounds from the SLU-PP-332 scaffold, so oral-bioavailability findings for those descendants must not be attributed to SLU-PP-332 itself.
Does not establish
Evidence boundary: This is a compound-identity and pharmacokinetic boundary.
Sources: Orally Active ERR Agonist Developed From SLU-PP-332 Scaffold
Supported
The verified SLU-PP-332 evidence base remains preclinical/analytical, and this package identifies no controlled human efficacy trial supporting its use as an exercise mimetic, obesity drug, or metabolic therapy.
Does not establish
Evidence boundary: Research popularity and commercial availability do not constitute human clinical evidence.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Human pharmacokinetics, toxicology, interactions, reproductive effects, cardiovascular effects, and long-term safety are not established.Safety Consideration
Systemic ERR activation may affect multiple tissues and metabolic programs; beneficial mouse findings do not establish human safety.Safety Consideration
Online products cannot be assumed to match the compound used in published studies.Safety Consideration
Cardiac rhythm, contractility, remodeling, and blood-pressure effects follow from pan-ERR activation. Altered thermogenesis, appetite, glucose, and lipid metabolism, and possible proliferative or tumor-context effects from chronic nuclear-receptor signaling, remain unstudied in humans. Interaction with exercise, diabetes drugs, stimulants, PPAR/AMPK agents, thyroid hormones, and cardiovascular drugs is unknown. Lack of oral bioavailability creates uncertain route-dependent exposure, and impurities, incorrect structure, solvents, sterility, and chronic toxicity are unverified for marketplace material.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Orally Active ERR Agonist Developed From SLU-PP-332 Scaffold | A medicinal-chemistry paper describes development of a newer, orally active ERR agonist starting from the SLU-PP-332 scaffold, explicitly noting that SLU-PP-332 itself lacks oral bioavailability and functions as a chemical probe/starting point for improved analogues. Evidence generated for the newer orally bioavailable analogue does not transfer to SLU-PP-332. |
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational research summary only. Not medical advice, diagnosis, treatment guidance, or a user guide. Investigational and low-evidence compounds may have substantial unknowns.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for SLU-PP-332
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.